Literature DB >> 29285978

ONC201 shows promise in AML treatment.

Holly Edwards1,2, Yubin Ge1,2,3.   

Abstract

Entities:  

Keywords:  ONC201; TRAIL; imipridone; leukemia

Mesh：

Substances：

Year:  2018        PMID： 29285978      PMCID： PMC5914881          DOI： 10.1080/15384101.2017.1421035

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

1.  First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.

Authors:  Mark N Stein; Joseph R Bertino; Howard L Kaufman; Tina Mayer; Rebecca Moss; Ann Silk; Nancy Chan; Jyoti Malhotra; Lorna Rodriguez; Joseph Aisner; Robert D Aiken; Bruce G Haffty; Robert S DiPaola; Tracie Saunders; Andrew Zloza; Sherri Damare; Yasmeen Beckett; Bangning Yu; Saltanat Najmi; Christian Gabel; Siobhan Dickerson; Ling Zheng; Wafik S El-Deiry; Joshua E Allen; Martin Stogniew; Wolfgang Oster; Janice M Mehnert
Journal:  Clin Cancer Res       Date:  2017-03-22       Impact factor: 12.531

Review 2.  Treatment of Relapsed/Refractory Acute Myeloid Leukemia.

Authors:  Prithviraj Bose; Pankit Vachhani; Jorge E Cortes
Journal:  Curr Treat Options Oncol       Date:  2017-03

3.  Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.

Authors:  Joshua E Allen; Gabriel Krigsfeld; Patrick A Mayes; Luv Patel; David T Dicker; Akshal S Patel; Nathan G Dolloff; Evangelos Messaris; Kimberly A Scata; Wenge Wang; Jun-Ying Zhou; Gen Sheng Wu; Wafik S El-Deiry
Journal:  Sci Transl Med       Date:  2013-02-06       Impact factor: 17.956

4.  Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.

Authors:  Varun V Prabhu; Mala K Talekar; Amriti R Lulla; C Leah B Kline; Lanlan Zhou; Junior Hall; A Pieter J Van den Heuvel; David T Dicker; Jawad Babar; Stephan A Grupp; Mathew J Garnett; Ultan McDermott; Cyril H Benes; Jeffrey J Pu; David F Claxton; Nadia Khan; Wolfgang Oster; Joshua E Allen; Wafik S El-Deiry
Journal:  Cell Cycle       Date:  2018-02-19       Impact factor: 4.534

5.  ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.

Authors:  Jo Ishizawa; Kensuke Kojima; Dhruv Chachad; Peter Ruvolo; Vivian Ruvolo; Rodrigo O Jacamo; Gautam Borthakur; Hong Mu; Zhihong Zeng; Yoko Tabe; Joshua E Allen; Zhiqiang Wang; Wencai Ma; Hans C Lee; Robert Orlowski; Dos D Sarbassov; Philip L Lorenzi; Xuelin Huang; Sattva S Neelapu; Timothy McDonnell; Roberto N Miranda; Michael Wang; Hagop Kantarjian; Marina Konopleva; R Eric Davis; Michael Andreeff
Journal:  Sci Signal       Date:  2016-02-16       Impact factor: 8.192

6.  Evolution of acute myelogenous leukemia stem cell properties after treatment and progression.

Authors:  Tzu-Chieh Ho; Mark LaMere; Brett M Stevens; John M Ashton; Jason R Myers; Kristen M O'Dwyer; Jane L Liesveld; Jason H Mendler; Monica Guzman; Jennifer D Morrissette; Jianhua Zhao; Eunice S Wang; Meir Wetzler; Craig T Jordan; Michael W Becker
Journal:  Blood       Date:  2016-07-15       Impact factor: 22.113

7.  A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.

Authors:  Isabel Arrillaga-Romany; Andrew S Chi; Joshua E Allen; Wolfgang Oster; Patrick Y Wen; Tracy T Batchelor
Journal:  Oncotarget       Date:  2017-05-12
  7 in total
  5 in total

1.  Thioridazine inhibits self-renewal in breast cancer cells via DRD2-dependent STAT3 inhibition, but induces a G1 arrest independent of DRD2.

Authors:  Matthew Tegowski; Cheng Fan; Albert S Baldwin
Journal:  J Biol Chem       Date:  2018-08-21       Impact factor: 5.157

Review 2.  Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy.

Authors:  Jenna L Carter; Katie Hege; Jay Yang; Hasini A Kalpage; Yongwei Su; Holly Edwards; Maik Hüttemann; Jeffrey W Taub; Yubin Ge
Journal:  Signal Transduct Target Ther       Date:  2020-12-18

Review 3.  Targeting mitochondrial respiration for the treatment of acute myeloid leukemia.

Authors:  Jenna L Carter; Katie Hege; Hasini A Kalpage; Holly Edwards; Maik Hüttemann; Jeffrey W Taub; Yubin Ge
Journal:  Biochem Pharmacol       Date:  2020-10-02       Impact factor: 5.858

4.  ONC201 demonstrates anti-tumorigenic and anti-metastatic activity in uterine serous carcinoma in vitro.

Authors:  Ziwei Fang; Jiandong Wang; Leslie H Clark; Wenchuan Sun; Yajie Yin; Weimin Kong; Stuart R Pierce; Lindsay West; Stephanie A Sullivan; Arthur-Quan Tran; Varun V Prabhu; Chunxiao Zhou; Victoria Bae-Jump
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

5.  ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro.

Authors:  Yingao Zhang; Yu Huang; Yajie Yin; Yali Fan; Wenchuan Sun; Xiaoling Zhao; Katherine Tucker; Allison Staley; Sarah Paraghamian; Gabrielle Hawkins; Varun Prabhu; Joshua E Allen; Chunxiao Zhou; Victoria Bae-Jump
Journal:  Front Oncol       Date:  2020-10-20       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.